Frontline Pembrolizumab Plus Lenvatinib Has Antitumor Activi

The first-line combination of lenvatinib and pembrolizumab elicited durable responses with a manageable safety profile in patients with non–clear cell renal cell carcinoma, according to findings from the phase 2 KEYNOTE-B61 trial.

Related Keywords

Vienna , Wien , Austria , Memorial Sloan Kettering Cancer Center , New York , United States , Manuela Schmidinger , Chan Lee , Database Consortium , University Of Vienna , International Metastatic , Chung Han Lee , Karnofsky Performance Status , Medical University , Pembrolizumab , Lenvatinib , Phase 2 Keynote B61 Trial Nct04704219 , Asco 2023 ,